This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings' Updates: Enzon Pharma

TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.

The following ratings changes were generated on Wednesday, May 20.

We've upgraded Enzon Pharmaceuticals (ENZN - Get Report) from sell to hold. Strengths include the company's increase in net income and expanding profit margins. However, we also find weaknesses including a decline in the stock price during the past year, generally poor debt management and disappointing return on equity.

Net income rose 307.6% compared with the same quarter last year, from $1.5 million to $6.2 million. Enzon's gross profit margin of 77.2% has increased from the year-ago quarter, but its 12.7% net profit margin trails the industry average. Revenue fell 0.3% since the year-ago quarter, though EPS increased. The debt-to-equity ratio or 5 is above the industry average, but the quick ratio of 4.6 implies an ability to cover short-term cash needs. Return on equity has decreased compared with the same quarter last year.

We've upgraded Fluor (FLR - Get Report) from hold to buy, driven by its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, compelling growth in net income and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

Revenue rose by 20.6% since the same quarter last year, and EPS are up, though we anticipate underperformance in the coming year relative to the company's two-year pattern of positive EPS growth. Fluor's debt-to-equity ratio of 0.1 is below the industry average, and its quick ratio of 1.1 implies an ability to avoid short-term cash problems. ROE has improved compared with the same quarter last year, and net income increased by 49.8%, from $136.7 million to $204.8 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ENZN $0.51 0.00%
FLR $54.66 0.00%
HD $133.89 0.00%
HMC $26.96 0.00%
UTX $104.37 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs